Levin Capital Strategies’s Inovio Pharmaceuticals INO Stock Holding History

Levin Capital Strategies’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,250	Closed	-$49K	–	202
2019 Q4	$49K	Buy	+1,250	New	+$37.6K	﹤0.01%	204
2019 Q2	–	Sell	-2,500	Closed	-$112K	–	215
2019 Q1	$112K	Buy	+2,500	New	+$126K	0.01%	181
2018 Q4	–	Sell	-1,667	Closed	-$111K	–	276
2018 Q3	$111K	Sell	1,667 -1,416	-46%	-$78.9K	﹤0.01%	257
2018 Q2	$145K	Buy	3,083 +1,375	+81%	+$75.8K	﹤0.01%	264
2018 Q1	$97K	Buy	+1,708	New	+$92.4K	﹤0.01%	290
2017 Q4	–	Sell	-4,425	Closed	-$337K	–	334
2017 Q3	$337K	Buy	4,425 +2,467	+126%	+$184K	0.01%	245
2017 Q2	$184K	Buy	1,958 +708	+57%	+$60.6K	﹤0.01%	284
2017 Q1	$99K	Buy	+1,250	New	+$99.6K	﹤0.01%	287

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Levin Capital Strategies's INO Position: Q1 2020 in Review

Levin Capital Strategies sold out of Inovio Pharmaceuticals (INO) in Q1 2020, closing a stake of 1,250 shares — an estimated $49K sold.

Levin Capital Strategies first reported a position in INO in Q1 2017 and held it in 8 quarters. The position peaked at $337K in Q3 2017. 158 funds tracked by Wall St. Rank hold INO as of Q1 2020.

Levin Capital Strategies reported no remaining Inovio Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Levin Capital Strategies sold 1,250 Inovio Pharmaceuticals shares in Q1 2020, an estimated $49K.
Levin Capital Strategies first reported a position in Inovio Pharmaceuticals in Q1 2017 and held it in 8 quarters.
Levin Capital Strategies's Inovio Pharmaceuticals position peaked at $337K in Q3 2017.
158 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2020.

Based on Levin Capital Strategies's 13F filing for Q1 2020, filed 13 May 2020.